RecruitingNot ApplicableNCT07192081

Comparative Efficacy of Intravenous Labetalol and Lignocaine in Mitigating Hemodynamic Responses to Laryngoscopy During Laparoscopic Cholecystectomy

Comparative Efficacy of Intravenous Labetalol and Lignocaine in Mitigating Hemodynamic Responses to Laryngoscopy During Laparoscopic Cholecystectomy: A Randomized Controlled Trial


Sponsor

Dr. Waseem Ullah

Enrollment

116 participants

Start Date

Jun 5, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Laryngoscopy and intubation during laparoscopic cholecystectomy often cause sudden increases in heart rate and blood pressure, which can be harmful in some patients. Medications such as labetalol and lignocaine are commonly used to reduce this hemodynamic response. This randomized controlled trial at Hayatabad Medical Complex, Peshawar, will compare intravenous labetalol (0.25 mg/kg) and lignocaine (1.5 mg/kg), administered 3 minutes before laryngoscopy. A total of 116 patients undergoing elective laparoscopic cholecystectomy will be randomly assigned to either drug group. The primary goal is to determine which drug is more effective in keeping heart rate and mean arterial pressure within ±20% of baseline during and after intubation. The study will also record blood pressure trends, intubation details, rescue medications, and adverse events such as bradycardia or hypotension. Results will help guide anesthesiologists in selecting the safer and more effective option to maintain cardiovascular stability during surgery.


Eligibility

Min Age: 18 YearsMax Age: 60 Years

Inclusion Criteria5

  • ASA Grade I and II
  • Age 18 to 60 years
  • Elective laparoscopic cholecystectomy
  • Both genders
  • Informed consent given

Exclusion Criteria7

  • Hypersensitivity to labetalol/lignocaine
  • Hypertensive on antihypertensives
  • ASA Grade III or more
  • Cardiovascular, renal, hepatic, or endocrine issues
  • Pregnant/lactating
  • BMI ≥ 35
  • Anticipated difficult airway

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLabetalol

Labetalol 0.25 mg/kg intravenous bolus over 60 seconds, administered 3 minutes before laryngoscopy.

DRUGLignocaine

Lignocaine 1.5 mg/kg intravenous bolus over 60 seconds, administered 3 minutes before laryngoscopy.


Locations(1)

Hayatabad Med Complex

Peshawar, Khyber Pakhtunkhwa, Pakistan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07192081


Related Trials